Differential effects of diethylstilbestrol and 2,3,7,8-tetrachlorodibenzo-p-dioxin on thymocyte differentiation, proliferation, and apoptosis in bcl-2 transgenic mouse fetal thymus organ culture

被引:38
作者
Lai, ZW
Fiore, NC
Hahn, PJ
Gasiewicz, TA
Silverstone, AE [1 ]
机构
[1] SUNY Upstate Med Univ, Dept Microbiol & Immunol, Syracuse, NY 13210 USA
[2] SUNY Upstate Med Univ, Dept Radiat Oncol, Syracuse, NY 13210 USA
[3] Univ Rochester, Sch Med, Environm Hlth Sci Ctr, Dept Environm Med, Rochester, NY 14642 USA
关键词
diethylstilbestrol; 2,3,7,8-tetrachlorodibenzo-p-dioxin; thymus; apoptosis; cellular differentiation; cellular proliferation; immunomodulators; transgenics;
D O I
10.1006/taap.2000.9015
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Both the estrogenic drug diethylstilbestrol (DES) and the pervasive environmental contaminant 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) inhibit thymocyte development. The mechanisms by which either agent induces thymic atrophy are still undetermined. We previously found that TCDD and DES inhibited C57BL/6 murine fetal thymocyte organ cultures (FTOC) at different stages of development. Now, using bcl-2 transgenic (TG) mice, we have further investigated their effects on FTOC proliferation, differentiation, maturation, and apoptosis. As with C57BL/6 mice, thymocyte development in C3H/bcl-2 FTOCs was inhibited by either TCDD (10 nM) or DES (20 mu M) in both bcl-2 TG- and TG+ littermates, However, the percentage reduction of cell number induced by DES in bcl-2 TG+ FTOCs was significantly less than the level of inhibition in TG- FTOCs, There was no difference in the level of reduction from TCDD-exposed TG+ or TG- FTOC. Whereas TCDD increased production of mature CD8 cells in either strain, DES mainly yielded cells in the CD4(-)CD8(-) (DN) stage in TG- mice. The anti-apoptotic bcl-2 transgene overcame some DES blocking of DN thymocyte development, allowing more cells to differentiate into CD4 single-positive cells. Analysis of cell cycle showed that TCDD inhibited entry into S phase, whereas DES blocked cell cycling in the G2/M phase. TCDD did not induce detectable apoptosis in FTOC. However, unlike the effects of 17 beta-estradiol (E2) in vivo, DES induced apoptosis in the TG- FTOC, and these apoptotic cells were mainly in the DN subpopulation. This apoptosis could be prevented by the overexpression of bcl-2 in the TG+ mice. Our results demonstrate that, in addition to inhibition of fetal thymocytes at different stages of development by TCDD and DES, DES also induces thymic atrophy by both bcl-2-inhibitable apoptosis and by inducing cell cycle arrest in G2/M in the latest stage in the stem cell compartment, TCDD, on the other hand, does not induce apoptosis, but inhibits entry into cell cycle in the earliest stage in the stem cell compartment. (C) 2000 Academic Press.
引用
收藏
页码:15 / 24
页数:10
相关论文
共 51 条
[1]   Tissue distribution of estrogen receptors alpha (ER-alpha) and beta (ER-beta) mRNA in the midgestational human fetus [J].
Brandenberger, AW ;
Tee, MK ;
Lee, JY ;
Chao, V ;
Jaffe, RB .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1997, 82 (10) :3509-3512
[2]   TISSUE-SPECIFIC EXPRESSION OF THE RAT AH-RECEPTOR AND ARNT MESSENGER-RNAS [J].
CARVER, LA ;
HOGENESCH, JB ;
BRADFIELD, CA .
NUCLEIC ACIDS RESEARCH, 1994, 22 (15) :3038-3044
[3]  
COMMENT CE, 1992, J PHARMACOL EXP THER, V262, P1267
[4]   TIME-COURSE OF 2,3,7,8-TETRACHLORODIBENZO-P-DIOXIN (TCDD)-INDUCED THYMIC ATROPHY IN THE WISTAR RAT [J].
DEHEER, C ;
VERLAAN, APJ ;
PENNINKS, AH ;
VOS, JG ;
SCHUURMAN, HJ ;
VANLOVEREN, H .
TOXICOLOGY AND APPLIED PHARMACOLOGY, 1994, 128 (01) :97-104
[5]   PROGRAMMED DIFFERENTIATION OF MURINE THYMOCYTES DURING FETAL THYMUS ORGAN-CULTURE [J].
DELUCA, D ;
BLUESTONE, JA ;
SHULTZ, LD ;
SHARROW, SO ;
TATSUMI, Y .
JOURNAL OF IMMUNOLOGICAL METHODS, 1995, 178 (01) :13-29
[6]  
Donner KJ, 1999, CYTOMETRY, V35, P80, DOI 10.1002/(SICI)1097-0320(19990101)35:1<80::AID-CYTO11>3.3.CO
[7]  
2-#
[8]   THE KINETICS OF IMMATURE MURINE THYMOCYTE DEVELOPMENT INVIVO [J].
EGERTON, M ;
SHORTMAN, K ;
SCOLLAY, R .
INTERNATIONAL IMMUNOLOGY, 1990, 2 (06) :501-507
[9]  
Forsberg JG, 1996, ACTA ANAT, V157, P275
[10]  
GASIEWICZ TA, 1984, MOL PHARMACOL, V26, P90